stimulates oxygen consumption
Also Known As:
L-6-ketopiperidine-2-carbonyl-leucyl-proline amide; Piladox; RGH 2202; RGH-2202; pAad-Leu-Pro-NH2; posatireline; pyro-2-aminoadipoyl-leucyl-prolinamide; L-Prolinamide, N-((6-oxo-2-piperidinyl)carbonyl)-L-leucyl-, (S)-
Networked: 16 relevant articles (6 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Jaworska-Feil, L: 2 articles (12/2010 - 01/2001)
2. Budziszewska, B: 2 articles (12/2010 - 01/2001)
3. Lipkowski, A W: 1 article (12/2010)
4. Basta-Kaim, A: 1 article (12/2010)
5. Kubera, M: 1 article (12/2010)
6. Leskiewicz, M: 1 article (12/2010)
7. Lason, W: 1 article (12/2010)
8. Jantas, D: 1 article (12/2010)
9. Pantoni, Leonardo: 1 article (11/2004)
10. Sarkadi, Adám: 1 article (01/2002)

Related Diseases

1. Alzheimer Disease (Alzheimer's Disease)
08/01/1995 - "Posatirelin (L-pyro-2-aminoadipyl-L-leucil-L-prolinamide) a new synthetic tripeptide with cholinergic, catecholaminergic and neurotrophic properties, was investigated in the treatment of Alzheimer's disease. "
01/01/1998 - "In order to confirm the efficacy and safety of posatirelin (L-pyro-2-aminoadipyl-L-leucyl-L-prolinamide), a synthetic peptide having cholinergic, catecholaminergic and neurotrophic activities, a multicentre, double-blind, controlled study versus placebo was planned in elderly patients suffering from Alzheimer's disease and vascular dementia, according to National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and National Institute of Neurological Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN) criteria, respectively. "
08/01/1995 - "Posatirelin for the treatment of late-onset Alzheimer's disease: a double-blind multicentre study vs citicoline and ascorbic acid."
11/15/2004 - "The conclusions of the present review are that: (1) some drugs such as nicergoline, memantine, posatirelin, propentofylline, and pentoxifylline have shown some, although partly limited, benefits in VaD patients; (2) besides a lack of efficacy of the tested drugs, possible causes of the negative results of many randomized clinical trials in VaD are the enrollment of patients with heterogeneous subtypes of VaD, the small sample size, and the use of end-points and cognitive tests inadequate for the VaD setting because derived from previous experience in the field of Alzheimer disease. "
2. Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy)
3. Seizures (Seizure)
4. Dementia (Dementias)
5. Shock

Related Drugs and Biologics

1. Pentoxifylline (Trental)
2. Nicergoline
3. Memantine (Namenda)
4. Kainic Acid (Kainate)
5. propentofylline
6. Neuroprotective Agents
7. Proline (L-Proline)
8. Cytidine Diphosphate Choline (Citicoline)
9. Ascorbic Acid (Vitamin C)
10. montirelin (NS-3)